Cowen Cuts Price target on Finish Line (FINL) to $22 Following 2Q16

UBS Cuts Price Target on Finish Line (FINL) Following 2Q SSS Miss

September 28, 2015 9:14 AM EDT

UBS remains Neutral on Finish Line (NASDAQ: FINL), and cuts the price target to $21.00 (from $29.00), following the company's 2Q SSS miss.

Analyst Michael Binetti commented, "We were disappointed in FINLs 2Q SSS miss (+1.5% vs. our +4% est), elevated inventory levels (+11% YOY vs. sales... More

Unusual 11 Mid-Day Movers 9/25: (BLPH) (ANFI) (JBL) Higher; (EMES) (PETX) (GLPG) Lower

September 25, 2015 1:53 PM EDT

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 95.7% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for INOpulse, which will... More

Pre-Open Stock Movers 09/25: (BLPH) (SIEN) (NKE) Higher; (INAP) (FINL) (PIR) Lower (more...)

September 25, 2015 9:29 AM EDT

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 50% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's... More

Finish Line (FINL) Reports In-Line Q2 EPS, Maintains FY16 Comp Guidance

September 25, 2015 7:12 AM EDT

Finish Line (NASDAQ: FINL) reported Q2 EPS of $0.57, in-line with the analyst estimate of $0.57. Revenue for the quarter came in at $483.2 million versus the consensus estimate of $491.15 million.

Finish Line comparable store sales increased 1.5%.

Finish Line sees FY2016 EPS of $1.67 vs... More

After Hours Stocks Movers 09/24: (BLPH) (NKE) (MRVL) Higher; (INAP) (PIR) (BBBY) (more...)

September 24, 2015 5:53 PM EDT

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 61% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for... More

Nike (NKE) Peers Trade Higher in Sympathy Following Q1 Beat (UA) (FINL) (FL) (SKX)

September 24, 2015 4:59 PM EDT

Nike (NYSE: NKE) peers traded higher after-hours Thursday after it reported stronger than expected Q1 results

Related names include:

Finish Line (NASDAQ: FINL)Under Armour (NYSE: UA)Skechers USA (NYSE: SKX)Foot Locker (NYSE: FL)
... More

Trading Radar for 9/25: BlackBerry (BBRY), Finish Line (FINL) Report

September 24, 2015 2:35 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Q2 GDP: Third Estimate - Street sees 3.7%

Earnings:

BlackBerry (Nasdaq: BBRY) - consensus loss $0.09... More

Notable Analyst Rating Changes 9/23: (RTN) (FINL) (BIDU) Upgraded; (SHW) (BTE) (KMX) Downgraded

September 23, 2015 10:28 AM EDT

UPGRADES
Bernstein upgrades Raytheon (NYSE: RTN) from Market Perform to Outperform with a price target of $132.

FBR Capital raises Finish Line (Nasdaq: FINL) from Market Perform to Outperform... More

Piper Jaffray Remains Bullish on Finish Line (FINL) Ahead of 2Q16 Results

September 23, 2015 7:14 AM EDT

Piper Jaffray reiterated an Overweight rating and $31.00 price target on Finish Line (NASDAQ: FINL) ahead of the company's 2Q16 earnings results. FINL is expected to report its earnings on September 25.

Analyst Erinn Murphy commented, "Shares of FINL has steeply reversed in the... More

FBR Capital Upgrades Finish Line (FINL) to Outperform

September 23, 2015 6:22 AM EDT

FBR Capital upgraded Finish Line (NASDAQ: FINL) from Market Perform to Outperform with a price target of $30.00 (from $28.00), saying the sneaker trend is in the company's sweet spot and valuation crates an attractive entry point.

Analyst Susan Anderson commented, "We are upgrading shares of FINL to Outperform from Market Perform. At only 12.4x consensus FY17 EPS, FINL is... More